5 December 2022 NEXT GENERATION Natural Killer Cells  Engineered to Beat Cancer Exhibit 99.2

Forward-looking statements This presentation contains forward‐looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding future events and the future results of the company that are based on current expectations, estimates, forecasts, and projections about the industry in which the company operates and the future of our business, future plans and strategies, projections, anticipated trends and events, the economy, and other future conditions, and the beliefs and assumptions of the management of the company. Words such as “address,” “anticipate,” “believe,” “consider,” “continue,” “develop,” “estimate,” “expect,” “further,” “goal,” “intend,” “may,” “plan,” “potential,” “project,” “seek,” “should,” “target,” “will,” variations of such words, and similar expressions are intended to identify such forward-looking statements. Such statements reflect the current views of the company and its management with respect to future events and are subject to inherent risks, uncertainties, and changes in circumstances that are difficult to predict and may be outside our control. Therefore, you should not rely on any of these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the company's actual results, performance, or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. Please see section entitled “Risk Factors” in our annual, quarterly and other filings with the Securities and Exchange Commission for a description of these risks and uncertainties. This presentation has been prepared by the company based on information it has obtained from sources it believes to be reliable. Summaries of documents contained in this presentation may not be complete. The company does not represent that the information herein is complete. The information in this presentation is current only as of the date on the cover, and the company's business or financial condition and other information in this presentation may change after that date. The company undertakes no obligation to update any forward‐looking statements in order to reflect any event or circumstance occurring after the date of this presentation or currently unknown facts or conditions. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more data on existing patients become available. The clinical trial program is ongoing, and the final results may be materially different from those reflected in any interim data the company reports. Further, others, including regulatory agencies, may not accept or agree with the company’s assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and the value of the company in general. In addition, the information the company chooses to publicly disclose regarding a particular study or clinical trial is typically a summary of extensive information, and you or others may not agree with what the company determines is the material or otherwise appropriate information to include in its disclosure, and any information the company determines not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or business.

Next generation platform built for: CAR NK cells driving a revolution in off-the-shelf cell therapy Allogeneic, off-the-shelf, and on demand Industrialized manufacturing Outpatient administration Targeting receptor CAR NK Cell OX40 costimulatory domain CD3ζ signaling moiety CAR membrane bound IL-15 Blood cancers and solid tumors

Best response for 6 additional patients treated since April update Follow-up on patients from April update, including multiple patients with durability beyond 6 months Tolerability and clinical impact of additional cycles of NKX019 Deepening Consolidation Retreatment Outpatient administration in multiple patients Opening of dose expansion cohorts NKX019: Key topics for discussion

NKX019 for the Treatment of Relapsed / Refractory  B-Cell Malignancies  Clinical Data as of 28 November 2022

CAR T-cell therapy is not accessible to most patients with NHL Only 20-30% of patients with LBCL that can benefit from cell therapy receive it Potential for toxicity requires close proximity to an intensive care unit Need for specialized sites as >25% of patients require ICU care  Grade 3+ CRS: 13 to 49%, Grade 3+ ICANS / neurotoxicity: 18 to 31% Only 30-40% of patients with LBCL treated with CAR T-cell therapy have 6-month CR No ability to re-dose for incomplete response Outcomes among those that relapse is poor Autologous CAR T-cell therapy has set the bar for cellular therapies in relapsed / refractory NHL but has limitations YESCARTA USPI; KYMRIAH USPI; BREYANZI USPI; Azoulay et al, 2020; Tomas, et al. 2022. CAR: chimeric antigen receptor; CR: complete response; CRS: cytokine release syndrome;ICANS: immune cell associated neurotoxicity syndrome; ICU: intensive care unit; LBCL: large B-cell lymphoma; NHL: non- lymphoma; USPI: U.S. Prescribing Information. NKX019

r/r CD19+ B-cell malignancies Received >2 priorlines of therapy ECOG PS 0 or 1 CAR T-cell therapy naïve (dose-finding phase) Endpoints:  Safety and tolerability Anti-tumor activity Pharmacokinetics NKX019 for B-cell malignancies: A multicenter, open-label, phase 1 study NKX019 3 doses per 28-day cycle Lymphodepletion Cyclophosphamide 300 mg/m2/day IV (dose-finding phase) Fludarabine 30 mg/m2/day IV Days -5 to -3 Efficacy assessment* Day 28 Day 0 Day 7 Day 14 Dose 1 Dose 2 Dose 3 NCT05020678 EOT Visit Post-treatment follow-up Subjects with initial clinical benefit and subsequent progression may receive retreatment *Efficacy based on: Lugano criteria for NHL; 2018 iwCLL guidelines for CLL; NCCN v1.2020 for B-ALL  CAR: chimeric antigen receptor; CR: complete response; ECOG PS: Eastern Cooperative Oncology Group performance status; EOT: end of therapy; r/r: relapsed/refractory; iwCLL: International Workshop on Chronic Lymphocytic Leukemia; NCCN: National Comprehensive Cancer Network.  Multiple cycles allowed to deepen response for subjects tolerating and benefiting from treatment Subjects in CR may receive additional cycle as consolidation Key Inclusion Criteria

Patients who were treated with NKX019 were heavily pre-treated and had a poor prognosis 50% 4 7 of 14 patients with NHL had aggressive LBCL Median lines of prior therapy NKX019 Total (N=19) Age, median (range) 59 (21-82) Baseline ECOG PS 1 13 Australia/US 13/6 Diagnosis   Large B cell lymphoma (LBCL)#       IPI 3+ 7 3 (43%)   Follicular lymphoma (FL)       FLIPI high risk 5 3 (60%)   Marginal zone lymphoma (MZL) 1   Mantle cell lymphoma (MCL) 1   Chronic lymphocytic leukemia (CLL) 2   B-cell acute lymphoblastic leukemia (B-ALL) 3 Prior lines of therapy, median (range) 4 (2 - 10) DLBCL: diffuse large B-cell lymphoma; ECOG PS: Eastern Cooperative Oncology Group performance status; FL3b: follicular lymphoma grade 3b; FLIPI: Follicular Lymphoma International Prognostic Index; LBCL: large B-cell lymphoma; NHL: non-Hodgkin lymphoma. #LBCL includes 6 DLBCL and 1 FL3b.

NKX019 was well-tolerated up to 1.5 B cells / dose No ICANS / neurotoxicity, GVHD, Grade 5 or dose-limiting toxicities One (5%) Grade ≥ 3 infection No treatment-related AEs leading to discontinuation of NKX019 Myelosuppression, consistent with standard lymphodepletion, was the most common Grade ≥ 3 toxicity and manageable Treatment-emergent AEs regardless of relationship. Grade 3/4 AEs in >1 subject Total (N=19)​ Subjects with any ≥ Grade 3 AEs  16 (84%) Neutrophil count decreased 12 (63%) Platelet count decreased 8 (42%) Febrile neutropenia  5 (26%) Anemia 4 (21%) WBC count decreased 3 (16%) Lymphocyte count decreased 2 (11%) AE: adverse event; GVHD: graft versus host disease; ICANS: immune effector cell-associated neurotoxicity syndrome. WBC: white blood cell count.

A minority of patients experienced transient and manageable infusion-related effects 5/19 patients (26%) developed fever within 8 hours that resolved within 24 hours In contrast, CAR T-cell therapy–associated CRS has a median onset of 2-5 days and a median duration of 5-8 days Grade 1/2 infusion-related reactions (IRR) listed as expected side effect in Investigator’s Brochure No apparent association between symptoms and response * Lee, ASTCT. YESCARTA USPI; KYMRIAH USPI;  BREYANZI USPI. CAR: chimeric antigen receptor; CRS: cytokine release syndrome; G: grade.  Patient Grade* Investigator assessment Anti-IL-6 therapy Steroids Description of event #1 G1 IRR N N Fever within 8 hours; resolved with antipyretics and did not recur #2 G1 IRR N N Fever within 5 hours; resolved with antipyretics and did not recur #3 G2 CRS N N Fever and hypotension within 8 hours; resolved with antipyretics and did not recur G1 CRS N N Fever within 6 hours; resolved with antipyretics and did not recur #4 G3 CRS Y Y Fever and hypoxia within 5 hours; fever resolved within 24 hours and did not recur #5 G1 IRR N N Tachycardia (no fever) within 3 hours; resolved within 24 hours without intervention G2 CRS Y N Fever with hypotension and hypoxia within 6 hours; symptoms resolved within 24 hours after treatment and did not recur

Peak IL-6, IFNγ, IL-10, and IL-8 levels were marginally above baseline throughout treatment for most patients Severe (Grade > 3) CRS in those receiving CAR T-cell therapies is generally associated with ~100-fold changes of multiple serum cytokines No Grade > 3 CRS observed to datewith NKX019 No association was observed between elevated serum cytokines and clinical response Cytokine elevation was generally modest across all patients CAR: chimeric antigen receptor; CR: complete response; CRS: cytokine release syndrome. M. Davila et al., Sci Transl Med. 2014; Hay et al., Blood, 2017.

NKX019 showed monotherapy activity across multiple histologies ​ 300 M Cells × 3 Doses​ 1 B Cells × 3 Doses 1.5 B Cells × 3 Doses​ ​ ORR (CR, PR)​ CR​ ORR (CR, PR)​ CR​ ORR (CR, PR)​ CR​ All NHL​ 2/4​ 1/4 ​ 5/6​ (83%) 4/6 ​(67%) 3/4 (75%)​ 3/4 (75%)​ LBCL#​ 1/3​ 0/3​ 1/2​ 1/2​ 1/2​ 1/2​ MCL​ -​ -​ 1/1​ 1/1​ -​ -​ FL​ 1/1​ 1/1​ 2/2​ 1/2*​ 2/2​ 2/2 MZL​ -​ -​ 1/1​ 1/1​ -​ -​ ​ ​ ​ Leukemia​ ​0/1 0/1​ 0/2​ ​0/2 ​0/2 ​0/2 ALL​ 0/1​ 0/1 0/2 0/2​ -​ -​ CLL​ -​ -​ -​ -​ 0/2 [1/2 SD]​ 0/2​ New since April 2022 * PR deepened to CR since April 2022 8/10 ORR (80%), including 7/10 CRs (70%) observed at higher dose levels in NHL #LBCL includes DLBCL and FL3b. ALL: acute lymphoblastic leukemia; CLL: chronic lymphocytic leukemia; CR: complete response; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; FL3b: follicular lymphoma grade 3b; LBCL: large B-cell lymphoma; MCL: mantle cell lymphoma; MZL: marginal zone lymphoma; NHL: non-Hodgkin lymphoma; ORR: overall response rate; PR: partial response.

NKX019 monotherapy elicited complete responses with early durability across NHL histologies; most responses occurred after a single cycle​ 1 1.5 B FL CR 2 1.5 B LBCL CR 3 1.5 B FL CR 4 1.5 B LBCL SD 5 1.0 B LBCL CR 6 1.0 B MZL CR 7 1.0 B FL CR 8 1.0 B MCL CR 9 1.0 B FL PR 10 1.0 B LBCL SD 11 300 M FL CR 12 300 M FL3b PR 13 300 M LBCL PD 14 300 M LBCL PD CR: complete response; FL: follicular lymphoma; FL3b: follicular lymphoma grade 3b; LBCL: large B-cell lymphoma; MCL: mantle cell lymphoma; MZL: marginal zone lymphoma; PD: progressive disease; PR: partial response; SD: stable disease. Best Response Patient Cells CR PR Indeterminant SD PD Death Transplant Eligible for Retreatment NHL Subtype 8 patients achieved CR with NKX019 monotherapy 5 after a single cycle 3 with PR deepened to CR with additional cycles 7 received consolidation cycle Retreatment planned with 1.5 B dose for 3 patients New since April 2022

Nearly every patient with NHL treated with NKX019 experienced tumor reduction​ Notes: 1. Tumor size is calculated as sum of the product of the perpendicular diameters (SPD). 2. One patient discontinued due to clinical progression without SPD assessment. 3. One patient did not have any target lesions. The SPD was calculated based on measurable non-target lesions. CR: complete response; NHL: non-Hodgkin lymphoma; PD: progressive disease; PR: partial response.  Best Response CR PR SD PD

Higher cell doses correlated with higher peak measured concentration (Cmax) Peak concentration trended higher in patients achieving CR Higher peak concentrations of NKX019 correlated with complete responses and higher doses of NKX019 6.7 = Lower limit of quantification Cmax, given as transgene copies/μg of DNA.   Dose Level Cmax All subjects CR Non-CR 300 M cells n 5 1 4 Median (range) < 6.7  (< 6.7-393) 393  (393) < 6.7 (< 6.7-234) 1 B/1.5 B cells n 14 7 7 Median(range) 156.9 (< 6.7-567.0) 298 (< 6.7-567.0) < 6.7 (< 6.7-481) CMAX, peak detected concentration; CR: complete response.

Successive rounds of NKX019 are feasible and effective at achieving clinical responses Median interval between treatment cycles was 8 days Lymphodepletion was given at the beginning of each 28-day cycle of therapy and was well-tolerated 40% of eligible patients received NKX019 in the outpatient setting after first cycle Mandatory 24-hour admission after each dose in the first cycle Increased outpatient utilization observed with increased experience  On demand availability of NKX019 facilitated successive treatment cycles and outpatient administration

CAR T-cell therapy–naïve LBCL cohort Improved access and favorable safety profile Comparable CR rate to autologous CAR T CAR T-cell therapy–experienced LBCL cohort CD19 expression persists in >90% of those who fail CAR T-cell therapy; outcomes for these patients are poor1 NKX019 offers NK-driven cytotoxicity and superior sensitivity to CD19 antigen2 Rituximab combination cohort Dual antigen targeting through ADCC and improved anti-tumor activity of NKX0193 CAR T-naïve and CAR T-experienced NKX019 expansion cohorts are now open, each using 1.5 B cell dose and updated lymphodepletion 2 3 NKX019 has greater cytotoxicity than CAR T cells against a low CD19 expressing cell line Effector:Target Ratio NKX019 has enhanced tumor cell killing when combined with rituximab 1. Tomas, et al. Leukemia 2022; 2.Dickinson, et al. ASH 2021; 3.Thome, et al. SITC 2022.  ADCC: antibody-dependent cell-mediated cytotoxicity; CAR: chimeric antigen receptor;CR: complete response; LBCL: large B-cell lymphoma. 

NKX019 remains on track for potential registration-enabling studies Allogeneic and off-the-shelf cell therapy to improve patient access Evaluation of monotherapy activity as well as in combination with rituximab Strong cash position: $395 million as of September 30, with runway into 2025 Clinical data strengthen Nkarta’s position in the NHL therapeutic landscape 18 ​ 2022​ 2023​ 2024​ ​ H1​ H2​ H1​ H2​ H1​ H2​ NKX019 ​ NHL ​ ​ ​ ​ ​ ​ ​ ​ Potential for fast track / RMAT / breakthrough therapy designation H1 H2 H1 H2 H1 H2 Pivotal Trials Monotherapy Dose Expansion:CAR T-naïve LBCL cohort Phase 1 Dose Finding: B cell malignancies Monotherapy Dose Expansion: CAR T-experienced LBCL cohort  Rituximab Combination Dose Expansion:  CAR T-naïve and -experienced CAR: chimeric antigen receptor; LBCL: large B-cell lymphoma; NHL: non-Hodgkin lymphoma; Ph: phase.

Building on earlier data, NKX019 monotherapy continues to be well-tolerated with promising anti-tumor activity Six additional patients with r/r NHL have been treated since prior data cut-off Earlier reported PR deepened to CR CR rate improved to 70% from previous update of 50% On-demand availability for administration in the outpatient setting No DLTs, ICANS, GVHD, or Grade > 3 CRS At highest dose levels, 8 of 10 patients with NHL responded (80% ORR), and 7 of 10 patients achieved complete responses (70% CR)  CRs observed in multiple NHL histologies, including 50% CR in LBCL Nearly every patient with NHL treated with NKX019 had tumor reduction Deepening of response and consolidation of CR achieved with multiple cycles Potential for retreatment should tumor recur Deep responses with durability exceeding 6 months in multiple patients Expansion cohorts now open for enrollment  NKX019 is an accessible, off-the-shelf CAR NK cell therapy with encouraging activity and safety profile CAR: chimeric antigen receptor; CR: complete response; CRS: cytokine release syndrome; DLT: dose-limiting toxicity; GVHD: graft versus host disease; ICANS: immune effector cell-associated neurotoxicity syndrome; LBCL: large B-cell lymphoma; NHL: non-Hodgkin lymphoma; ORR: overall response rate: Ph: phase; r/r: relapsed/refractory.